Vita 34 AG has a Successful Start in Current Fiscal Year 2017

– Revenues increased in the first three months by 7.1 percent to EUR 4.1 million

– Further positive development of EBITDA following completed integration of subsidiaries

– Dynamic growth trend will be continued in 2017 with planned acquisition of Seracell Pharma

Leipzig, 16 May 2017 – Vita 34 AG (WKN A0BL84) the second largest stem cell bank in Europe, has started the current fiscal year extraordinarily successfully. In the first three months of 2017, revenues increased by 7.1 percent to EUR 4.1 million, as compared with the proportional prior year’s value (Q1 2016: EUR 3.8 million). Total operating income also increased by 8.4 percent to EUR 4.3 million (Q1 2016: EUR 4.0 million).

The continuous increase of EBITDA observed in the past year is ongoing with an increasing dynamic. EBITDA attained EUR 0.7 million, thus nearly doubling as compared with the prior year’s figure (Q1 2016: EUR 0.3 million). Simultaneously, selling costs were reduced by 15.7 percent to EUR 1.6 million. Vita 34 improved the EBITDA margin from 8.3 percent (Q1 2016) to 17.3 percent.

Dr. André Gerth, Chairman of the Management Board of Vita 34 AG, commented: “This decrease in selling costs and the EBITDA improvement are a reflection of the positive, synergetic effects and economies of scale resulting from the integration of our new subsidiaries. In 2017 we will also pursue our Buy and Build strategy consistently.”

At the beginning of the year Vita 34 increased its existing majority position in its subsidiary Stellacure by acquiring additional shares resulting in a 95.24 percent position, with the goal of fully integrating the company into the group. In the middle of the year Vita 34 also plans to take over Seracell Pharma AG. With this acquisition Vita 34 will succeed in achieving another jump in the increase of significant key group figures, as well as in the number of stored stem cell deposits.

Here, Dr. André Gerth expounded: “With the acquisition of Seracell Pharma AG we would not only further expand our market leadership in the DACH region, but we would also assure ourselves a major strategic advantage in the international arena. Additionally, there would be numerous synergetic effects, primarily in Germany. Even now, Vita 34 has an extremely attractive business model, which generates increasingly stable, recurring revenues that result from long-term contractual periods.”

The complete quarterly report for the first three months of 2017 is available immediately for download on the Internet at www.vita34group.de in the Investor Relations section.

Company Profile

Vita 34 was founded in 1997 as the first private umbilical cord blood bank in Europe and, as a complete provider, offers collection logistics, preparation and storage of umbilical cord blood and cord tissue. The basis for its successful work is an outstanding position in the technological segment of cryo-preservation. Here, cells and tissue are preserved alive at some -190ºC for long periods of time, and can be used if needed in the context of medical treatment. Some 160,000 families are already taking advantage of this offering and have provided for their children with a stem cell deposit at Vita 34.